Guggenheim Remains Bullish Ahead of Teva Pharma's (TEVA) AGN Deal
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/31/2026
Go back to Guggenheim Remains Bullish Ahead of Teva Pharma's (TEVA) AGN Deal
April 18, 2016 8:31 AM EDT
JERUSALEM--(BUSINESS WIRE)--
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it
will release its first quarter 2016 financial results on Monday, May 9,
2016 at 7:00 a.m. ET.
Teva will host a conference call and live webcast on the same day, at
8:00 a.m. ET to discuss its first quarter 2016 results and overall
business environment. A Question & Answer session will follow this
discussion.
In order to participate, please dial the following numbers (at least 10
minutes before the scheduled start time): United States 1-866-254-0808;
Canada 1-866-607-2172 or... More
April 18, 2016 8:01 AM EDT
First-HD Study shows improvements in Total Motor Score and Swallowing
Function in Huntington disease patients treated with SD-809
JERUSALEM--(BUSINESS WIRE)--
Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today
announced new data from the Phase III placebo-controlled and randomized First
Time Use of SD-809 in Huntington Disease
(First-HD) study evaluating the efficacy, safety and tolerability of
SD-809 (deutetrabenazine) for the treatment of chorea associated with
Huntington disease (HD). The data will be featured during two... More
